Testosterone improves antidepressant-emergent loss of libido in women: Findings from a randomized, double-blind, placebo-controlled trial

Journal of Sexual Medicine

Volumn 11, Issue 3, 2014, Pages 831-839

  Fooladi, Ensieh ^a   Bell, Robin J ^a   Jane, Fiona ^a   Robinson, Penelope J ^a   Kulkarni, Jayashri ^b   Davis, Susan R ^a  

^a MONASH UNIVERSITY   (Australia)

^b ALFRED HOSPITAL   (Australia)

Author keywords

Female Sexual Dysfunction; Loss of Libido; SNRI; SSRI; Testosterone

Indexed keywords

CITALOPRAM; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; PAROXETINE; PLACEBO; SERTRALINE; TESTOSTERONE; VENLAFAXINE;

ABDOMINAL PAIN; ADULT; ADVERSE OUTCOME; ARTHRALGIA; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; FEMALE; FEMALE SEXUAL FUNCTION INDEX; HUMAN; LEG FRACTURE; LIBIDO DISORDER; MIDDLE AGED; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SEXUAL SATISFACTION; TESTOSTERONE BLOOD LEVEL; TREATMENT OUTCOME;

FEMALE SEXUAL DYSFUNCTION; LOSS OF LIBIDO; SNRI; SSRI; TESTOSTERONE;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; ADULT; ANDROGENS; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LIBIDO; MIDDLE AGED; SELF REPORT; SEROTONIN UPTAKE INHIBITORS; SEXUAL BEHAVIOR; TESTOSTERONE; TREATMENT OUTCOME;

EID: 84895472020     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/jsm.12426     Document Type: Article

References (30)

1. Byles J, Loxton D, Berecki J, Doliza-Gore X, Gibson R, Hockey R, etal. Use and costs of medications and other health care resources: Findings from the Australian longitudinal study on women's health. University of Newcastle and the University of Queensland, 2008.
2. Williams VS, Baldwin DS, Hogue SL, Fehnel SE, Hollis KA, Edin HM. Estimating the prevalence and impact of antidepressant-induced sexual dysfunction in two European countries: A cross-sectional patient survey. J Clin Psychiatry 2006;67:204-210.
3. Montejo AL, Llorca G, Izquierdo JA, Rico-Villademoros F. Incidence of sexual dysfunction associated with antidepressant agents: A prospective multicenter study of 1022 outpatients. Spanish working group for the study of psychotropic-related sexual dysfunction. J Clin Psychiatry 2001;62(3 suppl):10-21.
4. Werneke U, Northey S, Bhugra D. Antidepressants and sexual dysfunction. Acta Psychiatr Scand 2006;114:384-397.
5. Nurnberg HG, Hensley PL, Heiman JR, Croft HA, Debattista C, Paine S. Sildenafil treatment of women with antidepressant-associated sexual dysfunction: A randomized controlled trial. JAMA 2008;300:395-404.
6. Schweitzer I, Maguire K, Ng C. Sexual side-effects of contemporary antidepressants:Review. Aust N Z J Psychiatry 2009;43:795-808.
7. Braunstein GD, Sundwall DA, Katz M, Shifren JL, Buster JE, Simon JA, etal. Safety and efficacy of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: A randomized, placebo-controlled trial. Arch Intern Med 2005;165:1582-1589.
8. Buster JE, Kingsberg SA, Aguirre O, Brown C, Breaux JG, Buch A, etal. Testosterone patch for low sexual desire in surgically menopausal women: A randomized trial. Obstet Gynecol 2005;105:944-952.
9. Simon J, Braunstein G, Nachtigall L, Utian W, Katz M, Miller S, etal. Testosterone patch increases sexual activity and desire in surgically menopausal women with hypoactive sexual desire disorder. J Clin Endocrinol Metab 2005;90:5226-5233.
10. Shifren J, Davis SR, Moreau M, Waldbaum A, Bouchard C, DeRogatis L, etal. Testosterone patch for the treatment of hypoactive sexual desire disorder in naturally menopausal women: Results from the INTIMATE NM1 study. Menopause 2006;13:770-779.
11. Davis SR, van der Mooren MJ, van Lunsen RHW, Lopes P, Rees M, Moufarege A, etal. The efficacy and safety of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: A randomized, placebo-controlled trial. Menopause 2006;13:387-396.
12. Davis SR, Moreau M, Kroll R, Bouchard C, Panay N, Gass M, etal. Testosterone for low libido in menopausal women not taking estrogen therapy. N Engl J Med. 2008;359:2005-2017.
13. Davis SR, Papalia MA, Norman RJ, O'Neill S, Redelman M, Williamson M, etal. Safety and efficacy of a testosterone metered-dose transdermal spray for treatment of decreased sexual satisfaction in premenopausal women: A placebo-controlled randomized, dose-ranging study. Ann Intern Med 2008;148:569-577.
14. Goldstat R, Briganti E, Tran J, Wolfe R, Davis SR. Transdermal testosterone therapy improves well-being, mood, and sexual function in premenopausal women. Menopause 2003;10:390-398.
15. Shifren JL, Braunstein G, Simon J, Casson P, Buster JE, Red Burki RE, etal. Transdermal testosterone treatment in women with impaired sexual function after oophorectomy. N Engl J Med. 2000;343:682-688.
16. Procter and Gamble Pharmaceuticals I. Advisory Committee Briefing Document. Intrinsa® (testosterone transdermal system) NDA no. 21-769. Washington, DC: US Food and Drug Administration. 2004. Available at: http://www.fda.gov/ohrms/dockets/ac/04/briefing/2004-4082B1_01_A-P&G-Intrinsa.pdf (accessed January 7, 2014).
17. Beck AT, Steer RA, Brown GK. Manual for the beck depression inventory-II. San Antonio, TX: The Psychological Corporation, Harcourt, Brace and Co.; 1996.
18. Bell RJ, Lijovic M, Fradkin P, Davis SR. A pragmatic approach to the classification of menopausal status for community-based research. Menopause 2008;15:978-983.
19. Fedor-Freybergh P. The influence of estrogens on the wellbeing and mental performance in climacteric and postmenopausal women. Acta Obstet Gynecol Scand 1977;64(suppl):1-91.
20. Garratt A, Torgerson D, Wyness J, Hall M, Reid DM. Measuring sexual function in pre menopausal women. Br J Obstet Gynaecol 1995;102:311-316.
21. DeRogatis L, Clayton A, Lewis-D'Agostino D, Wunderlich G, Fu Y. Validation of the female sexual distress scale-revised for assessing distress in women with hypoactive sexual desire disorder. J Sex Med 2008;5:357-364.
22. Dupuy H. The psychological general well-being (PGWB) index. In: Wenger N, Mattson M, Furberg C, Elinson J, eds. Assessment of quality of life in clinical trials of cardiovascular therapies. New York: Le Jacq Publishing; 1984:170-183.
23. McNair DM, Lorr M, Droppleman LF. Manual for the profile of mood States. San Diego, CA: EdITS Educational and Industrial testing Service; 1992.
24. Ferriman D, Gallwey JD. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab 1961;21:1440-1447.
25. Palatsi R, Hirvensalo E, Liukko P, Malmiharju T, Mattila L, Riihiluoma P, etal. Serum total and unbound testosterone and sex hormone binding globulin (SHBG) in female acne patients treated with two different oral contraceptives. Acta Derm Venereol 1984;64:517-523.
26. Panjari M, Bell RJ, Jane F, Wolfe R, Adams J, Morrow C, etal. A randomized trial of oral DHEA treatment for sexual function, well-being, and menopausal symptoms in postmenopausal women with low libido. J Sex Med 2009;6:2579-2590.
27. Armitage PGB. Statistical methods inmedical research. 3rd edition. Oxford UK: Blackwell Scientific Publications; 1994.
28. Davis SR, Goldstat R, Papalia MA, Shah SM, Kulkarni J, Donath S, etal. Effects of aromatase inhibition on sexual function and wellbeing in postmenopausal women treated with testosterone: A randomized placebo controlled trial. Menopause 2006;13:37-45.
29. Vermeulen A, Verdonck L, Kaufman M. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 1999;84:3666-3672.
30. Labrie F. Intracrinology. Mol Cell Endocrinol 1991;78:C113-118.